• 1
    Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005; 13(4):219227.
  • 2
    Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol. 2011; 22(1):3038.
  • 3
    Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol. 2006; 4(2 Suppl 1):38.
  • 4
    Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006; 24(27):44724478.
  • 5
    Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist. 2007; 12(9):11431150.
  • 6
    Hesketh PJ, Van Belle S, Aapro M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003; 39(8):10741080.
  • 7
    Rubenstein EB, Slusher BS, Rojas C, Navari RM. New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006; 12(5):341347.
  • 8
    Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010; 21(Suppl 5):v232v243.
  • 9
    Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2011; 29(31):41894198.
  • 10
    NCCN Clinical Practice Guidelines in Oncology: Antiemesis Version 1. 2014;
  • 11
    Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007; 15(5):497503. Epub 2006 Nov. 14.
  • 12
    Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Shelke AR. Biobehavioral factors in chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw. 2004; 2(5):501508. Review.
  • 13
    Salsman JM, Grunberg SM, Beaumont JL, et al. Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Canc Netw. 2012; 10(2):149157.
  • 14
    Rizzi A, Campi B, Camarda V, et al. In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist Netupitant. Peptides. 2010; 37(1):8697.
  • 15
    Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003; 14(10):15701577.
  • 16
    Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003; 98(11):24732482.
  • 17
    Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009; 10(2):115124. Epub 2009 Jan. 8. Erratum in: Lancet Oncol. 2010;11(3):226.
  • 18
    Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006; 17(9):14411449.
  • 19
    Rojas C, Li Y, Zhang J, et al. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther. 2010; 335(2):362368. Epub 2010 Aug. 19.
  • 20
    Rojas C, Slusher BS. Pharmacological mechanism of 5-HT3 and tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012; 684(1–3):17. Epub 2012 Mar. 9.
  • 21
    Stathis M, Pietra C, Rojas C, Slusher BS. Inhibition of substance P-mediated responses in NG 108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol. 2012; 689(1–3):2530.
  • 22
    Gardner CJ, Armour DR, Beattie DT, et al. GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul Pept. 1996; 65(1):4553.
  • 23
    Bergström M, Fasth K-J, Kilpatrick G, et al. Brain uptake and receptor binding of two [11C]-labelled high affinity NK1 antagonists, GR203040 and GR205171—PET studies in rhesus monkey. Neuropharmacology. 2000; 39(4):664670.
  • 24
    Michelgård A, Appel L, Pissiota A, et al. Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol Psychiatry. 2007; 61(8):10021006. Epub 2006 Sept. 1.
  • 25
    Solin O, Eskola O, Hamill TG, et al. Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK1 receptor quantitation: ([18F]SPA-RQ). Mol Imaging Biol. 2004; 6(6):373384.
  • 26
    Bergström M, Hargreaves RJ, Burns DH, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry. 2004; 55:10071012.
  • 27
    Hietala J, Nyman MJ, Eskola O, et al. Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Mol Imaging Biol. 2005; 7(4):262272.
  • 28
    Nyman MJ, Eskola O, Kajander J, et al. Gender and age affect NK1 receptors in the human brain—a positron emission tomography study with [18F]SPA-RQ. Int J Neuropsychopharmacol. 2007; 10(2):219229. Epub 2006 Mar. 30.
  • 29
    Andersson JLR. A rapid and accurate method to realign PET scans utilizing image edge transformation. J Nucl Med. 1995; 36:657669.
  • 30
    Patlak CS, Blasberg R. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985; 5:584590.
  • 31
    Wolfensberger SPA, van Berckel BNM, Airaksinen AJ, et al. First evaluation of [11C]R116301 as an in vivo tracer of NK1 receptors in man. Mol Imaging Biol. 2009; 11(4):241245.
  • 32
    Van Laer K, De Hoon J, Bormans G, et al. Equivalent dyanamic human brain NK-1 receptor occupancy following single-dose IV fosaprepitant vs. oral aprepitant as assessed by PET imaging. Clin Pharmacol Ther. 2012; 92(2):243250.
  • 33
    Helsinn Internal Report: Determination of Netupitant and Its Metabolites, M1, M2, and M3 Concentrations in Human Plasma and Urine Samples from Study NETU-09-21, December 2011.
  • 34
    Caberlotto L, Hurd YL, Murdock P, et al. Neurokinin 1 receptor and relative abundance of the short and long isoforms in human brain. Eur J Neurosci. 2003; 17:17361746.
  • 35
    Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry. 2002; 63(Suppl 11):1824.
  • 36
    Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006; 59(3):216223. Epub 2005 Oct. 24.
  • 37
    Hesketh P, Rossi G, Rizzi G, et al. Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC). J Clin Oncol. 2013; 31 (suppl; abstr 9512J).
  • 38
    Aapro M, Rossi G, Rizzi G, Palmas M, Grunberg S. Phase 3 study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC). J.Clin Oncol. 2013; 31 (suppl; abstr LBA9514).
  • 39
    Jordan K, Rossi G, Rizzi G, Palmas M, Gralla RJ. NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting (CINV) following repeated chemotherapy cycles: Results of a phase 3 trial. J Clin Oncol. 2013; 31 (suppl; abstr e20716).
  • 40
    Zamuner S, Rabiner EA, Fernandes SA, et al. A pharmacokinetic PET study of NK1 receptor occupancy. Eur J Nucl Med Mol Imaging. 2012; 39(2):226235. Epub 2011 Oct. 13.